PHARMACY

Ateb forms Community Pharmacy Advisory Board

BY Antoinette Alexander

RALEIGH, N.C. — Ateb, a provider of pharmacy patient care solutions, has announced the formation of its inaugural Community Pharmacy Advisory Board, comprised of pharmacy leaders who will serve as an “internal institute” within the Ateb organization.

The group will address industry issues and position community pharmacy partners as industry leaders in delivering coordinated, quality patient care and driving healthier outcomes. By identifying and understanding key challenges, Ateb and the CPAB will work to develop solutions to allow independent community pharmacies to improve patient engagement, optimize medication use, streamline overall pharmacy management and leverage value-based opportunities to create and expand new revenue streams.

Ateb and the CPAB will analyze the collective findings to increase the awareness and adoption of innovative care solutions, allowing pharmacies to transform to an appointment based model and improve the quality of patient care to benefit patients, pharmacies, and payers. Ateb will use the insights provided by CPAB members to make business decisions to enhance the development of strategic solutions in order to meet the future needs of the community pharmacy.

Through a collaborative approach, Ateb and the CPAB will offer a platform where pharmacists may exchange experiences, best practices and ideas with their peers that will effectively increase their business optimization and improve their pharmacy operations.

Ateb’s Community Pharmacy Advisory Board consists of 23 members, and features a mix of community pharmacy partners and Ateb’s executive team.  The CPAB held its first meeting in May at Ateb’s headquarters in Raleigh.

Community pharmacy partners comprising the inaugural CPAB:
Darran Alberty – D&H Drugstore
Tanya Alberty – D&H Drugstore
Amy Baloh – Hometown Pharmacy
Jana Bennett – Medicine Shoppe Pharmacies 306 and 708
Tim Clark – Clark’s Rx Pharmacy
John Coler – Shrivers Pharmacy
Sammy Elayan – Hayat Pharmacy
Omar Eliwa – Hayat Pharmacy
Bob Lomenick – Tyson Drug Co.
John Nord – Nords Pharmacy and Gifts, Thrifty White Affiliates
Bill Osborn – Osborn Drugs
Dared Price – Graves Drugs
Lance Wheeler – Medicap 8290
Jarred Witt – Owens Healthcare
Tim and Nora Wright – Wagner Pharmacy
Hashim Zaibak – Hayat Pharmacy                      
 
The following members of Ateb’s executive team will serve on the CPAB:

Frank Sheppard, president and CEO
Debbie Sheppard, VP, sales and marketing
Rebecca Chater, executive healthcare strategist
Mark Gregory, VP, healthcare solutions
Ken Monroe, partner coaching and consulting
Mike Cantrell, VP, pharmacy network development
Robbert Ayshford, VP, strategic solutions
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study: Pharmaceutical companies lag in Hispanic-targeted ad spending

BY Antoinette Alexander

FAIRFAX, Va. — According to a new report from national trade organization AHAA: the Voice of Hispanic Marketing, pharmaceutical marketers have room for improvement when it comes to Hispanic advertising.

According to AHAA, pharmaceutical marketers increased their aggregate Hispanic advertising investment by only 4% between 2010 and 2014 to $165 million. Among the top 500 U.S. advertisers, the pharmaceutical category allocation to Hispanic dedicated media remained basically unchanged at 2.5%, which is significantly less than the national average of 8.5%.

Despite research supporting the importance of the Hispanic market to corporate bottom lines, the average Hispanic ad spend by pharmaceutical companies decreased 9% from $6.9 million to $6.3 million in 2014. According to the organization, this category remains at a "laggard" allocation level, defined as companies who assign 1% to 3.5% of their marketing budget to Hispanic dedicated efforts.

Over the past five years, the top 500 advertisers boosted their spending in Hispanic-targeted media by 63% or $2.7 billion from $4.3 billion in 2010 to $7.1 billion. The top 500 advertisers boosted their average spending from $9 million in Hispanic-targeted media in 2010 to today's $14 million.

Data was collected from Nielsen Monitor Plus, which tracked more than 340,000 companies' advertising expenditures in English and Spanish. This data was analyzed by Santiago Solutions Group for AHAA. SSG divided companies into five tiers according to the percent allocation to Spanish/Bilingual media: Best-in-Class (more than 14.2%), Leaders (6.4%-14.2%), Followers (3.6%-6.3%), Laggards (1%-3.5%), and On the Sidelines (Less than 1%).

SSG also segmented the Top 500 overall spending (English + Spanish) companies for years 2010 to 2014, thus permitting the analysis of trends in the marketplace. Ad spend Includes spending in Network TV, Spot TV, Cable TV, radio, magazines, newspaper and FSIs. It excludes B2B, display, outdoor and cinema.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: Medicare Part D plans less apt to cover opioids with abuse deterrents

BY DSN STAFF

Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility. In particular, the research shows that Medicare Part D plans cover generic opioids that lack abuse-deterrent features at a higher rate than it covers branded opioids. 
 
“While there has been significant attention on the development and approval of new abuse-deterrent drug products, there has been noticeably less consideration of access to such products,” Avalere CEO Dan Mendelson said.
 
Particularly with regard to oxycodone hydrochloride, the brand-name OxyContin received approval from the Food and Drug Administration in 2013 for abuse-deterrent labeling, but since 2012, Part D plan coverage for it has dropped from 61% to 46%. On the other hand, every Part D plan covers generic oxycodone hydrochloride. As a result, seniors have less access to safer opioids.
 
“While prescription opioid abuse continues to be a priority for public health experts and lawmakers, coverage for these products by Part D plans is limited and plans are increasingly favoring lower-cost generic products on their formularies,” Avalere SVP Caroline Pearson said. “Policymakers seeking to limit opioid abuse will have to balance the desire for greater access to abuse-deterrent opioids with the increased costs of such medications to public programs and private payers.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?